UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934 (Amendment No. 3)*

Eyenovia, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value

(Title of Class of Securities)

30234E 104

(CUSIP Number)

Fred Eshelman 295 Madison Avenue, Suite 2400 New York, NY 10017 917-289-1117

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

August 19, 2020

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(g), check the following box. \Box

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See section 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Page 1 of 4 Pages)

CUSIP No. 30234E 104 Pages

1	Names of Reporting Persons.						
	First Fabrican						
2	Fred Eshelman Check the Appropriate Box if a Member of a Group						
2	(a) \square						
	(a) □ (b) □						
	(5) —						
3	SEC Use Only	SEC Use Only					
4	Source of Funds (S	Source of Funds (See Instructions)					
	PF						
5	= =	Pr Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) □					
5	Check if Disclosur	e of Legal Pro	ceedings is Required Pursuant to Items 2(d) or 2(e)				
6	Citizenship or Plac	Citizenship or Place of Organization					
	United States	United States					
		7	Sole Voting Power				
			(1)				
	Number of	8	1,691,440 ⁽¹⁾				
	Shares Beneficially		Shared Voting Power				
			0				
	Owned by	9	Sole Dispositive Power				
	Each		Sole Bisposiure Forter				
	Reporting Person With		1,691,440 ⁽¹⁾				
			Shared Dispositive Power				
			0				
11	Aggregate Amount Beneficially Owned by Each Reporting Person						
		1,691,440 ⁽¹⁾					
12	Check if the Aggre	Check if the Aggregate Amount in Row (11) Excludes Certain Shares □					
13	Percent of Class R	Percent of Class Represented by Amount in Row (11)					
	6.8%						
14	Type of Reporting Person						
	INI						
	IN						

(1) Includes (i) 1,285,499 shares of common stock and 86,856 shares underlying options held by Fred Eshelman directly that are exercisable within 60 days of the date of this report and (ii) 319,085 shares of common stock held by Eshelman Ventures, LLC. Dr. Eshelman is the manager of Eshelman Ventures, LLC and, therefore, may be deemed to have beneficial ownership of the shares of common stock held by Eshelman Ventures, LLC.

CUSIP No. 30234E 104 Pages

SCHEDULE 13D

This Amendment No. 3 on Schedule 13D amends the statement on Schedule 13D, dated February 20, 2018, which relates to the common stock, par value \$0.0001 per share (the "Common Stock") of Eyenovia, Inc. (the "Issuer") filed by Dr. Eshelman (the "Reporting Person"), which was previously amended on Schedules 13D/A, dated July 11, 2019 and August 12, 2020.

This Amendment No. 3 on Schedule 13D is being filed to show the change in percentage of beneficial ownership held by the Reporting Person as a result of the change in outstanding shares of Common Stock of the Issuer as reported by the Issuer to the Reporting Person on August 25, 2020. Except as expressly amended below, the Schedule 13D, dated February 20, 2018, which was previously amended on Schedules 13D/A, dated July 11, 2019 and August 12, 2020, remain in effect.

Item 5. <u>Interest in Securities of the Issuer</u>

(a)-(b) The aggregate number and percentage of Common Stock beneficially owned by the Reporting Person (on the basis of a total of 24,833,804 shares of Common Stock outstanding as of August 25, 2020) are as follows:

a)		Amount beneficially owned: 1,674,345	Percentage: 6.8%
b)		Number of shares to which the Reporting Person has:	
	i.	Sole power to vote or to direct the vote:	1,691,440 ⁽¹⁾
	ii.	Shared power to vote or to direct the vote:	0
	iii.	Sole power to dispose or to direct the disposition of:	1,691,440 ⁽¹⁾
	iv.	Shared power to dispose or to direct the disposition of:	0

(1) Includes (i) 1,285,499 shares of Common Stock and 86,856 shares underlying options held by the Reporting Person directly that are exercisable within 60 days of the date of this report and (ii) 319,085 shares of Common Stock held by Eshelman Ventures, LLC. The Reporting Person is the manager of Eshelman Ventures, LLC and, therefore, may be deemed to have beneficial ownership of the shares of common stock held by Eshelman Ventures, LLC.

CUSIP No. 30234E 104 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 28, 2020 /s/ Fred Eshelman

Fred Eshelman